skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Antibody targeting of TSG101 on influenza-infected cells

Original Research

(1771) Views  (379) Full article downloads

Authors: Aurelio Bonavia, Leyla S Diaz, David Santos, et al

Published Date November 2010 Volume 2010:2 Pages 147 - 157
DOI: http://dx.doi.org/10.2147/VAAT.S13506

Aurelio Bonavia1*, Leyla S Diaz1*, David Santos1, Josephine Cassella1, Zena Fesseha1, Douty Bamba1, Baoquan Sui1, Wu-Bo Li1, Roxanne Duan1, Li-Mei Chen2, Ruben O Donis2, Michael Goldblatt1, Michael S Kinch1
1Functional Genetics, Inc, Gaithersburg, MD, USA; 2Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA; *These authors contributed equally to this work.

Abstract: Influenza remains a significant cause of morbidity and mortality worldwide. Although vaccination programs and conventional antiviral therapies can reduce disease burden, increasing resistance to conventional therapies renders much of the population susceptible to infection. The present study focuses on an important host protein target, tumor susceptibility gene 101 (TSG101), which is functionally exploited (hijacked) by certain enveloped viruses to facilitate viral budding and release. We find that influenza viruses depend on TSG101 for progeny virion morphogenesis in infected host cells. Antibody-binding studies revealed that TSG101 is exposed at the surface of influenza-infected cells but remains intracellular in uninfected cells. Using recombinant TSG101 and influenza M1 protein, we demonstrated a direct interaction between these proteins involving the ubiquitin E2 variant domain of TSG101. These findings identify an interaction between TSG101 and M1 protein in infected cells. Furthermore, a monoclonal antibody directed against TSG101 reduced virus yields in cell-based assessment of influenza virus infection, underscoring the potential of the TSG101-M1 interaction as a possible antiviral therapeutic target. The display of TSG101 at the surface of infected cells, combined with evidence that TSG101 antibodies reduce virus yields, suggest that TSG101 plays an essential role in the budding process of influenza virus. Our findings may also suggest potential opportunities for influenza treatment and prevention by using monoclonal antibody therapeutics to interfere with virus replication.

Keywords: influenza, TSG101, infected cells, vaccine




 

Other articles by Dr M Kinch



Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Viral vectors for cystic fibrosis gene therapy: What does the future hold?
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
Asymmetric severity of diabetic retinopathy in Waardenburg syndrome: response to authors
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio